Dr. Michel J. Tremblay is a regular researcher in the field of infectious and immune diseases at the CHU Research Center of Québec-Laval University. He is also a Professor in the Department of Microbiology-Infectiology and Immunology of the School of Medicine at Laval University, and holds the Canada Research Chair in Human Immuno-Retrovirology.
He has been Vice-Dean, Research and Graduate Studies at the Faculty of Medicine, and is currently Assistant Vice-President, Research, Creation and Innovation at Laval University. Dr. Tremblay has published over 200 articles in peer-reviewed scientific journals, and to date has received nearly $ 15 million in funding as a principal investigator and just under $ 40 million in funding as co-researcher for his research projects. Dr. Tremblay has received several awards and distinctions, including the André Dupont Award from the Clinical Research Club of Quebec and the Léo-Pariseau Award from ACFAS. Dr. Tremblay is a member of the Canadian Research Consortium on HIV Healing (CanCURE) which is funded by the Canadian Institutes of Health Research (CIHR).
His research aims to deepen our knowledge of the pathogenesis of human immunodeficiency virus (HIV) infection, the etiologic agent of Acquired Immunodeficiency Syndrome (AIDS). His research focuses on several facets of HIV infection, such as the complex interactions that occur between HIV and certain target cells of the virus (e.g., macrophages, CD4 T cells, astrocytes, etc.) and large-scale analysis of gene expression patterns following viral infection, using DNA microarrays and RNA sequencing in combination with powerful bioinformatic tools.
2705, boulevard Laurier
R-2701.4
Québec, Québec
Canada G1V 4G2
- Barat, CorinneEmployeeCHUL+1 418-525-4444, extension 49333+1 418-654-2715corinne.barat@crchudequebec.ulaval.ca
2705, boulevard Laurier
R2701.6
Québec, Québec
Canada G1V 4G2 - Côté, CarolineEmployeeCHUL+1 418-525-4444, extension 48624+1 418-654-2715caroline.cote@crchudequebec.ulaval.ca
2705, boulevard Laurier
R-2740
Québec, Québec
Canada G1V 4G2 - Hany, LaurentEmployeeCHUL+1 418-525-4444, extension 48624laurent.hany.1@ulaval.caLaurent.Hany@crchudequebec.ulaval.ca
2705, boulevard Laurier
R-2740
Québec, Québec
Canada G1V 4G2
Infection of the Ex Vivo Tonsil Model by HTLV-1 Envelope-Pseudotyped Viruses
Journal ArticlePathogens, 12 (2), 2023.
Impact of latency-reversing agents on human macrophage physiology
Journal ArticleImmun Inflamm Dis, 11 (1), 2023.
Comparing Current and Next-Generation Humanized Mouse Models for Advancing HIV and HIV/Mtb Co-Infection Studies
Journal ArticleViruses, 14 (9), 2022.
Bryostatin-1 Decreases HIV-1 Infection and Viral Production in Human Primary Macrophages
Journal ArticleJ Virol, 96 (4), 2022.
Author Correction: Role of RIPK1 in SMAC mimetics-induced apoptosis in primary human HIV-infected macrophages
Journal ArticleSci Rep, 11 (1), 2021.
Role of RIPK1 in SMAC mimetics-induced apoptosis in primary human HIV-infected macrophages
Journal ArticleSci Rep, 11 (1), 2021.
The delicate balance between neurotoxicity and neuroprotection in the context of HIV-1 infection
Journal ArticleGlia, 69 (2), 2021.
The Balance between p53 Isoforms Modulates the Efficiency of HIV-1 Infection in Macrophages
Journal ArticleJ Virol, 95 (20), 2021.
Depot medroxyprogesterone acetate (DMPA) enhances susceptibility and increases the window of vulnerability to HIV-1 in humanized mice
Journal ArticleSci Rep, 11 (1), 2021.
Immunocompetent Human 3D Organ-Specific Hormone-Responding Vaginal Mucosa Model of HIV-1 Infection
Journal ArticleTissue Eng Part C Methods, 27 (3), 2021.
Active projects
- Canadian HIV Cure Enterprise 2.0: Targeting the interplay between myeloid cells and C04+ T-cells for HIV cure, from 2019-04-01 to 2024-03-31
- Contribution - consortium Érudit, from 2022-01-01 to 2024-04-30
- Microglia as a viral reservoir for HIV-1 in the human brain and its role in neuroinflammation, from 2021-04-01 to 2026-03-31
Recently finished projects
- Chaire du recherche du Canada en immuno-rétrovirologie humaine, from 2015-01-01 to 2021-12-31
- Manufacturing of antigens and adjuvants for development of vaccines (MAAV), from 2021-07-01 to 2023-03-31